Page 48 - GPD-3-3

Gene & Protein in Disease Phage therapy for Mycobacterium infections

the possible limitations of a single phage, which may be associated with implementing phage therapy on a large
ineffective against some bacterial strains or may develop scale, particularly beyond the scope of a clinical trial.
drug resistance. Utilizing combinations of multiple phages Primarily, the clinical utilization of phages as therapeutic
can enhance the bactericidal impact and diminish the agents in the field of medicine is still in its infancy.
likelihood of bacterial resistance to phages. Another Subsequent research efforts should focus on bolstering
approach is phage-antibiotic combination therapy. This clinical trials of phage therapy to ascertain its long-
strategy aims to enhance both the bactericidal and term effectiveness and safety in clinical practice, thereby
therapeutic effects of combining phages with antibiotics. establishing a robust basis for its widespread clinical
Broadly speaking, bacteriophages are viral agents that can application. In addition, the meticulousness of the
selectively infect and lyze target bacteria, while antibiotics preparation and purification process of phage therapy
impede bacterial growth and replication through diverse is crucial to ensuring its safety and efficacy. Further
mechanisms. The utilization of both bacteriophages and investigation is required to understand the specificity and
antibiotics offers several potential benefits. First, their selectivity of phages for different mycobacterial strains.
combined use can amplify their individual effects, as they Key areas of focus include developing screening techniques
operate through distinct mechanisms, thereby enhancing that can rapidly differentiate therapeutic phages from other
the bactericidal impact and leading to more efficient phages, devising effective phage treatment approaches to
eradication of bacterial infections. Second, this approach combat biofilms, establishing secure and validated phage
has the potential to mitigate and diminish drug resistance, preparation protocols for the production and preparation
as phages can selectively target specific bacterial strains, of larger-scale phages, and implementing conditions
thereby reducing the emergence of drug-resistant variants. to guarantee the stability of phages during storage and
When used in conjunction with antibiotics, this strategy transportation. Furthermore, clinical instances have
101
can lower the likelihood of bacteria developing resistance demonstrated that the combined use of bacteriophages
to drugs. There is also increased coverage. While certain and antibiotics yields superior outcomes. However, there
102
bacteria may develop resistance to phages or antibiotics is a lack of documented cases regarding the concurrent
individually, their combined use broadens the bactericidal administration of mycobacteriophages and associated
effect and enhances the likelihood of successful treatment. antibiotics. This gap highlights a potential avenue for
A study demonstrated that the mycobacteriophage SWU1 future investigation, which could offer novel insights
86
Gp39 serves as an antibiotic enhancer. Bacteriophages into managing mycobacterial infections. The potential
and antibiotics operate through distinct bactericidal of phages for treating mycobacterial infections remains
mechanisms, and their combined administration can largely unexplored, partly due to the limited availability of
yield synergistic effects. Finally, the manipulation of phages and insufficient understanding of factors such as the
bacteriophages through genetic engineering technology susceptibility and lethality of M. tuberculosis isolates from
to bolster their efficacy in treating specific diseases or different lineages, mechanisms of phage resistance, and
to enhance their safety and stability is referred to as interactions between phages and antibiotics. In general,
80
engineered bacteriophages. the potential applications of phages are poised to expand
Bacteriophages that target mycobacteria have further with ongoing research, presenting new prospects
demonstrated significant potential for medical applications, and challenges in medical therapy and biotechnology
particularly in the treatment of drug-resistant mycobacterial development. 103
infections. Mycobacteriophages offer a range of advantages 8. Conclusion
86
over conventional antibiotic therapy. First, phages are able
to selectively infect target bacteria without causing damage The use of mycobacteriophages in medicine offers
to normal human cells, thus minimizing potential toxic promising potential for the diagnosis and treatment of
effects. In addition, they have a wide host range and can Mycobacterium-associated infections, notably those caused
infect various types of mycobacteria, including drug- by M. tuberculosis, Mycobacteroides avium, and M. abscessus.
resistant strains. Furthermore, phage therapy can help Consequently, mycobacteriophages represent a promising
mitigate the issue of antibiotic resistance, providing a option for phage-based diagnostic and therapeutic
valuable alternative for patients who do not respond to approaches targeting mycobacterial infections.
conventional treatments. Bacteriophages, as natural antagonists of bacteria,

While phage therapy shows promise in improving present significant potential for application in the
the treatment of mycobacterial infections, several treatment of bacterial infections. However, the narrow
considerations must be taken into account to address the host range of bacteriophages poses a substantial limitation
unforeseeable challenges. There are notable complexities to the advancement and implementation of phage

Volume 3 Issue 3 (2024) 9 doi: 10.36922/gpd.2935